Doctor BPC-157

the sources

BPC-157 references and FDA sources

Every quantitative claim on this site maps to a numbered entry below. Peer-reviewed studies carry PMIDs and DOIs; regulatory facts cite FDA pages directly.

Back to the researchRead the FAQ

How to read this list

The BPC-157 references below are the complete citation set for this site. Entries [1] through [10] are peer-reviewed studies and reviews, identified by PubMed ID (PMID) and, where available, a DOI; each links to its PubMed record. Entries [11] through [13] are FDA pages that establish the regulatory and compounding facts on the BPC-157 legal status page. The preclinical record is overwhelmingly rodent; the three human pilots [5][6][7] are small and mostly uncontrolled, and are labeled as such throughout the site. Nothing on this site is cited that is not listed here.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  6. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
  7. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  8. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
  10. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
  11. FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (public calendar listing BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List). ↗
  12. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for 'BPC-157 (free base)' and 'BPC-157 acetate'; effective September 29, 2023). ↗
  13. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; the 503A/503B compounding framework; the January 7, 2025 revised interim policy). ↗